Cargando…

Muscarinic Receptor Signaling in Colon Cancer

According to the adenoma-carcinoma sequence, colon cancer results from accumulating somatic gene mutations; environmental growth factors accelerate and augment this process. For example, diets rich in meat and fat increase fecal bile acids and colon cancer risk. In rodent cancer models, increased fe...

Descripción completa

Detalles Bibliográficos
Autores principales: von Rosenvinge, Erik C., Raufman, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756399/
https://www.ncbi.nlm.nih.gov/pubmed/24212649
http://dx.doi.org/10.3390/cancers3010971
_version_ 1782282089484255232
author von Rosenvinge, Erik C.
Raufman, Jean-Pierre
author_facet von Rosenvinge, Erik C.
Raufman, Jean-Pierre
author_sort von Rosenvinge, Erik C.
collection PubMed
description According to the adenoma-carcinoma sequence, colon cancer results from accumulating somatic gene mutations; environmental growth factors accelerate and augment this process. For example, diets rich in meat and fat increase fecal bile acids and colon cancer risk. In rodent cancer models, increased fecal bile acids promote colon dysplasia. Conversely, in rodents and in persons with inflammatory bowel disease, low-dose ursodeoxycholic acid treatment alters fecal bile acid composition and attenuates colon neoplasia. In the course of elucidating the mechanism underlying these actions, we discovered that bile acids interact functionally with intestinal muscarinic receptors. The present communication reviews muscarinic receptor expression in normal and neoplastic colon epithelium, the role of autocrine signaling following synthesis and release of acetylcholine from colon cancer cells, post-muscarinic receptor signaling including the role of transactivation of epidermal growth factor receptors and activation of the ERK and PI3K/AKT signaling pathways, the structural biology and metabolism of bile acids and evidence for functional interaction of bile acids with muscarinic receptors on human colon cancer cells. In murine colon cancer models, deficiency of subtype 3 muscarinic receptors attenuates intestinal neoplasia; a proof-of-concept supporting muscarinic receptor signaling as a therapeutic target for colon cancer.
format Online
Article
Text
id pubmed-3756399
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-37563992013-09-04 Muscarinic Receptor Signaling in Colon Cancer von Rosenvinge, Erik C. Raufman, Jean-Pierre Cancers (Basel) Review According to the adenoma-carcinoma sequence, colon cancer results from accumulating somatic gene mutations; environmental growth factors accelerate and augment this process. For example, diets rich in meat and fat increase fecal bile acids and colon cancer risk. In rodent cancer models, increased fecal bile acids promote colon dysplasia. Conversely, in rodents and in persons with inflammatory bowel disease, low-dose ursodeoxycholic acid treatment alters fecal bile acid composition and attenuates colon neoplasia. In the course of elucidating the mechanism underlying these actions, we discovered that bile acids interact functionally with intestinal muscarinic receptors. The present communication reviews muscarinic receptor expression in normal and neoplastic colon epithelium, the role of autocrine signaling following synthesis and release of acetylcholine from colon cancer cells, post-muscarinic receptor signaling including the role of transactivation of epidermal growth factor receptors and activation of the ERK and PI3K/AKT signaling pathways, the structural biology and metabolism of bile acids and evidence for functional interaction of bile acids with muscarinic receptors on human colon cancer cells. In murine colon cancer models, deficiency of subtype 3 muscarinic receptors attenuates intestinal neoplasia; a proof-of-concept supporting muscarinic receptor signaling as a therapeutic target for colon cancer. Molecular Diversity Preservation International (MDPI) 2011-03-02 /pmc/articles/PMC3756399/ /pubmed/24212649 http://dx.doi.org/10.3390/cancers3010971 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
von Rosenvinge, Erik C.
Raufman, Jean-Pierre
Muscarinic Receptor Signaling in Colon Cancer
title Muscarinic Receptor Signaling in Colon Cancer
title_full Muscarinic Receptor Signaling in Colon Cancer
title_fullStr Muscarinic Receptor Signaling in Colon Cancer
title_full_unstemmed Muscarinic Receptor Signaling in Colon Cancer
title_short Muscarinic Receptor Signaling in Colon Cancer
title_sort muscarinic receptor signaling in colon cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756399/
https://www.ncbi.nlm.nih.gov/pubmed/24212649
http://dx.doi.org/10.3390/cancers3010971
work_keys_str_mv AT vonrosenvingeerikc muscarinicreceptorsignalingincoloncancer
AT raufmanjeanpierre muscarinicreceptorsignalingincoloncancer